Shares of Emergent Biosolutions Inc. (NYSE:EBS) were up 2.2% during mid-day trading on Tuesday . The company traded as high as $27.69 and last traded at $27.59, with a volume of 169,082 shares changing hands. The stock had previously closed at $26.99.

A number of analysts have recently issued reports on EBS shares. Singular Research dropped their price objective on shares of Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, June 28th. Wells Fargo & Co. restated a “buy” rating on shares of Emergent Biosolutions in a research note on Wednesday, June 22nd. Cowen and Company restated a “hold” rating and issued a $33.00 price target on shares of Emergent Biosolutions in a research note on Sunday, August 7th. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “sell” rating to a “hold” rating in a research note on Monday, July 4th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $40.00.

The company has a 50-day moving average price of $27.86 and a 200-day moving average price of $34.46. The firm has a market capitalization of $1.13 billion, a PE ratio of 20.03 and a beta of 1.24.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/emergent-biosolutions-inc-ebs-trading-up-2-2.html

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The firm earned $101.49 million during the quarter, compared to the consensus estimate of $111.20 million. Emergent Biosolutions had a net margin of 11.61% and a return on equity of 11.93%. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.36 EPS. On average, analysts forecast that Emergent Biosolutions Inc. will post $1.03 EPS for the current year.

Large investors have recently made changes to their positions in the stock. FIL Ltd purchased a new stake in shares of Emergent Biosolutions during the second quarter valued at approximately $16,063,000. Mesirow Financial Investment Management Equity Management bought a new stake in shares of Emergent Biosolutions during the second quarter worth about $15,439,000. Emerald Acquisition Ltd. bought a new stake in shares of Emergent Biosolutions during the second quarter worth about $13,280,000. Vanguard Group Inc. boosted its stake in shares of Emergent Biosolutions by 13.0% in the second quarter. Vanguard Group Inc. now owns 3,610,132 shares of the biopharmaceutical company’s stock worth $101,517,000 after buying an additional 415,470 shares during the last quarter. Finally, Numeric Investors LLC bought a new stake in shares of Emergent Biosolutions during the second quarter worth about $10,765,000. 91.27% of the stock is owned by institutional investors and hedge funds.

About Emergent Biosolutions

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

5 Day Chart for NYSE:EBS

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.